S1203: A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Determine the difference in effects of standard daunorubicin plus Cytarabine (AraC) vs. standard idarubicin plus AraC vs. idarubicin plus AraC and vorinostat (study drug).
Acute Myeloid Leukemia (AML)
- Greater than 18 and less than 60 years of age.
- Have previously untreated Acute Myeloid Leukemia (AML).
- Must not be pregnant or nursing.
18 - 60
Healthy Volunteers Needed
Duration of Participation
Up to 5 years after registration.
Knight Clinical Trials Office Information Line
Southwest Oncology Group (SWOG)